Literature DB >> 11204489

Oncogene activation and tumor suppressor gene inactivation find their sites of expression in the changes in time and space of the age-adjusted cancer incidence rate.

M Kodama1, T Kodama, M Murakami.   

Abstract

The purpose of the present investigation is to elucidate the relation between the distribution pattern of the age-adjusted incidence rate (AAIR) changes in time and space of 15 tumors of bothe sexes and the locations of centers of centripetal-(oncogene type) and centrifugal-(tumoe suppressor gene type) forces. The fitness of the observed log AAIR data sets to the oncogene type- and the tumor suppressor gene type-equilibrium models and the locations of 2 force centers were calculated by applying the least square method of Gauss to log AAIR pair data series with and without topological data manipulations, which are so designed as to let log AAIR pair data series fit to 2 variant (x, y) frameworks, the Rect-coordinates and the Para-coordinates. The 2 variant (x, y) coordinates are defined each as an (x, y) framework with its X axis crossed at a right angle to the regression line of the original log AAIR data (the Rect-coordinates) and as another framework with its X axis run in parallel with the regression line of the original log AAIR pair data series (the Para-coordinates). The fitness test of log AAIR data series to either the oncogene activation type equilibrium model (r = -1.000) or the tumor suppressor gene inactivation type (r = 1.000) was conducted for each of the male-female type pair data and the female-male type data, for each of log AAIR changes in space and log AAIR changes in time, and for each of the 3 (x, y) frameworks in a given neoplasia of both sexes. The results obtained are given as follows: 1) The positivity rates of the fitness test to the oncogene type equilibrium model and the tumor suppressor gene type model were each 63.3% and 56.7% with the log AAIR changes in space, and 73.3% and 73.3% with log AAIR changes in time, as tested in 15 human neoplasias of both sexes. 2) Evidence was presented to indicate that the clearance of oncogene activation and tumor suppressor gene inactivation is the sine qua non premise of carciniogenesis. 3) The r profile in which the correlation coefficient r, a measure of fitness to the 2 equilibrium models, is converted to either +(r > 0) or -(0 > r) for each of the original-, the Rect-, and the Para-coordinates was found to be informative in identifying a group of tumors with sex discrimination of cancer risk (log AAIR changes in space) or another group of environmental hormone-linked tumors (log AAIR changes in time and space)--a finding to indicate that the r-profile of a given tumor, when compared with other neoplasias, may provide a clue to investigating the biological behavior of the tumor. 4) The recent risk increase of skin cancer of both sexes, being classified as an example of environmental hormone-linked neoplasias, was found to commit its ascension of cancer risk along the direction of the centrifugal forces of the time- and space-linked tumor suppressor gene inactivation plotted in the 2-dimension diagram. In conclusion, the centripetal force of oncogene activation and centrifugal force of tumor suppressor gene inactivation found their sites of expression in the distribution pattern of a cancer risk parameter, log AAIR, of a given neoplasias of both sexes on the 2-dimension diagram. The application of the least square method of Gauss to the log AAIR changes in time and space, and also with and without topological modulations of the original sets, when presented in terms of the r-profile, was found to be informative in understanding behavioral characteristics of human neoplaisias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11204489

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  7 in total

1.  MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays.

Authors:  Huachuan Zheng; Hiroyuki Takahashi; Takahiko Nakajima; Yoshihiro Murai; Zhengguo Cui; Kazuhiro Nomoto; Koichi Tsuneyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-29       Impact factor: 4.553

2.  Expression profile of the REG gene family in colorectal carcinoma.

Authors:  Hua-chuan Zheng; Akira Sugawara; Hiroshi Okamoto; Shin Takasawa; Hiroyuki Takahashi; Shinji Masuda; Yasuo Takano
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

3.  ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.

Authors:  Wen-feng Gou; Dao-fu Shen; Xue-feng Yang; Shuang Zhao; Yun-peng Liu; Hong-zhi Sun; Rong-Jian Su; Jun-sheng Luo; Hua-chuan Zheng
Journal:  Oncotarget       Date:  2015-08-14

4.  Downregulated inhibitor of growth 3 (ING3) expression during colorectal carcinogenesis.

Authors:  Wen-feng Gou; Hong-zhi Sun; Shuang Zhao; Zhe-feng Niu; Xiao-Yun Mao; Yasuo Takano; Hua-chuan Zheng
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

5.  ING5 suppresses breast cancer progression and is regulated by miR-24.

Authors:  Shufang Cui; Xin Liao; Chao Ye; Xin Yin; Minghui Liu; Yeting Hong; Mengchao Yu; Yanqing Liu; Hongwei Liang; Chen-Yu Zhang; Xi Chen
Journal:  Mol Cancer       Date:  2017-05-10       Impact factor: 27.401

6.  The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.

Authors:  Shuang Zhao; Xue-Feng Yang; Dao-Fu Shen; Yang Gao; Shuai Shi; Ji-Cheng Wu; Hong-Xu Liu; Hong-Zhi Sun; Rong-Jian Su; Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2016-08-23

Review 7.  Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives.

Authors:  Sweta Nidhi; Uttpal Anand; Patrik Oleksak; Pooja Tripathi; Jonathan A Lal; George Thomas; Kamil Kuca; Vijay Tripathi
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.